Xenetic Biosciences, Inc. (NASDAQ:XBIO) Files An 8-K Regulation FD Disclosure
Xenetic Biosciences, Inc. Exhibit
EX-99.1 2 xenetic_ex9901.htm INVESTOR PRESENTATION Exhibit 99.1 Enhancing lives with transformative therapies www.xeneticbio.com NASDAQ: XBIO Corporate Presentation September 2019 Forward – Looking Statements This presentation contains forward – looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 . All statements contained in this presentation other than statements of historical facts may constitute forward – looking statements within the meaning of the federal securities laws . These statements can be identified by words such as “expects,…
To view the full exhibit click
About Xenetic Biosciences, Inc. (NASDAQ:XBIO)
Xenetic Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the research and development of certain pharmaceutical products for use in humans that includes the use of the Company’s platform technologies that enables the creation of drug therapies primarily for orphan indications. The Company’s technologies include PolyXen, Virexxa, OncoHist and ImuXen. The Company is focused primarily on developing its lead product candidates, including ErepoXen, Virexxa and OncoHist, and PolyXen technology. The Company’s lead product candidate ErepoXen, a polysialylated form of erythropoietin (EPO) for the treatment of anemia in pre-dialysis patients with chronic kidney disease, and Food and Drug Administration (FDA) orphan designated oncology therapeutics Virexxa and OncoHist for the treatment of progesterone receptor negative endometrial cancer and refractory Acute Myeloid Leukemia, respectively. It is also developing PSA-FVIII.